Found 180 articles
Artificial Intelligence (AI) in Drug Discovery Market To Set Remarkable CAGR Growth of 41.0% By 2029 | Analysed By key Players, Future Trends, Industry Growth And Applications Overview
A New Research on the Artificial Intelligence (AI) in Drug Discovery Market was conducted across a variety of industries in various regions to produce more than 350+ page reports.
Exscientia Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers
Exscientia Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A 2A Receptor Signaling Inhibition in Healthy Volunteers.
Owkin and BMS signed a deal to utilize Owkin's artificial intelligence capabilities to carry out more targeted and efficient clinical trials on a wide range of therapeutic candidates.
CHARM Therapeutics launches with a $50 million Series A financing to transform structure-based drug discovery using its proprietary DragonFold AI technology
CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research company discovering and developing transformational medicines founded by David Baker, Ph.D. and Laksh Aithani, announces today a $50M Series A financing co-led by F-Prime Capital and OrbiMed, with General Catalyst, Khosla Ventures, Braavos and Axial also participating.
Exscientia to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference.
Increasing prevalence various chronic diseases, rising adoption of cloud-based applications, and high focus on reducing costs of drug discovery and development are expected to drive global Intelligent Drug Discovery market growth.
Exscientia will host a conference call Thursday, May 26 at 1:30 p.m. BST / 8:30 a.m. ET to provide an overview of the Company's precision medicine platform.
According to Vision Research Reports, the Immuno-oncology Clinical Trials market size is expected to hit around US$ 25.1 billion by 2030 from valued at US$ 10.3 billion in 2020 and growing at a CAGR of 23.6% from 2021 to 2030.
Company to host conference call and webcast on May 26, 2022 at 1:30 p.m. BST / 8:30 a.m. ET.
Innovation community at The Oxford Science Park expands further as companies move into the Hayakawa Building
The innovation community at The Oxford Science Park, one of Europe's leading locations for science and technology companies, continues to expand as firms move into the newly refurbished Hayakawa Building.
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the first quarter ended March 31, 2022 and provided an update on recent program and corporate developments.
According to Report, the global AI in Drug Discovery Market was valued at USD 1.0 billion in 2021 and is projected to hit USD 10.80 billion by 2030, poised to grow at a CAGR of 36% from 2022 to 2030.
Exscientia announced that Ben Taylor, CFO & Chief Strategy Officer and Garry Pairaudeau, Chief Technology Officer, will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022 at 5:20 p.m. P.T.
According to Report Study, the global AI in Drug Discovery Market was valued USD 1.0 billion in 2021 and is set to reach USD 10.80 billion by 2030 and growing at a CAGR of 36% from 2022 to 2030.
Evotec SE reported financial results and corporate updates for the fiscal year ended 31 December 2021.
4/8/2022Onxeo, Amydis, eFFECTOR Therapeutics, Freenome, Urovant Sciences and others all added new guidance and perspectives to their C-suite this week.
Exscientia Presents Three Posters Demonstrating Potential of Precision Medicine Platform in Drug Discovery at the American Association of Cancer Research Annual Meeting 2022
Exscientia plc shared details of its participation at the upcoming American Association for Cancer Research Annual Meeting, taking place April 8-13 2022 at the Ernest N. Morial Convention Center in New Orleans, La. Exscientia scientists will present new research in three poster presentations.
Exscientia plc (Nasdaq: EXAI) today announced the appointment of Michael Krams, M.D., as its Chief Quantitative Medicine Officer.
According to Precedence Research, the global drug discovery market size is projected to hit US$ 161.76 billion by 2030 and is growing at a noteworthy CAGR of 8.9% from 2021 to 2030.
The personalized medicine market size was valued at US$ 2.12 trillion in 2021 and is projected to be worth around US$ 5.7 trillion by 2030 with a growing CAGR of 11.6% from 2021 to 2030.